An mRNA vaccine with immunotherapy may lower recurrence in melanoma, and active surveillance for prostate cancer has increased in the Veterans Affairs health system over the last two decades.
Ovarian cancer is often diagnosed at an advanced stage, but research is reshaping how scientists understand and treat the disease. From discoveries about its origins to new FDA-approved therapies, learn how scientific advances are...
Patients are waiting longer to start treatment than they did a decade ago, and an experimental pancreatic cancer drug is reaching patients ahead of FDA approval.
Antibody-drug conjugates, or ADCs, have emerged as a significant class of cancer therapies over the past two decades. New research has helped to revolutionize the drug class and deliver next-generation designs and approaches.
The new agent was approved in combination with daratumumab and hyaluronidase-fihj and dexamethasone for patients with resistant or refractory disease. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to iberdomide (Zenbexus)...
A variety of national and local news outlets have highlighted AACR initiatives and experts in recent weeks. Learn about the news stories covering the findings from the AACR Cancer Disparities Progress Report 2026 and...
Vusolimogene oderparepvec-wtpg and nivolumab earned accelerated approval to treat patients with advanced melanoma after PD-1 therapy. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to vusolimogene oderparepvec-wtpg (Tudriqev) in combination with...
Antibody-drug conjugates, or ADCs, are increasingly common cancer therapies. But what are they? How do they work? And how were they discovered? Learn about the history of ADCs, their functions, the ADCs currently approved...
We highlight some of the many innovations showcased at the inaugural AACR Drug Discovery and Development (AACR D3) conference, including investigational KRAS degraders, approaches to drug p53 and MYC, and new AI tools for...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More